Tumor infiltrating lymphocytes (TILs) are a significant predictor of prognosis in patients with breast cancer, especially for those with triple negative breast cancer (TNBC, ER-PR- without HER2 amplification) or certain ER+ subtypes [22,23,24]. This evidence concerns the gene ERBB2 and breast carcinoma.